Pappas Capital LLC
10/09/2015 | Press release | Archived content
ENVISIA THERAPEUTICS’ LEAD PRODUCT CANDIDATE, ENV515 (travoprost ...
News | 10. 09. 2015
Envisia Therapeutics
RESEARCH TRIANGLE PARK, NC - OCTOBER 6, 2015 - Envisia Therapeutics, a clinical-stage biotechnology company focused on the development of novel extended-release therapies in ophthalmology, today reported results from its first clinical trial of the Company's lead product candidate, ENV515 (travoprost XR). In this phase 2a trial, ENV515 achieved its primary efficacy endpoint by demonstrating a statistically significant and clinically meaningful reduction in intraocular pressure (IOP) with results comparable to topical once-daily TRAVATAN Z® (travoprost ophthalmic solution).
Pappas Capital LLC published this content on October 09, 2015, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 22, 2026 at 10:00 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]